A little-known immune cell could explain why some small cell lung cancer patients respond to immunotherapy

Researchers have identified that high levels of gamma delta T cells in small cell lung cancer tumors correlate with better responses to immunotherapy. This discovery could help clinicians predict patient outcomes and improve treatment strategies for this aggressive cancer.
Why it matters
Provides a potential biomarker for immunotherapy efficacy, which could save costs and improve survival rates for lung cancer patients.
Patients whose small cell lung cancer (SCLC) tumors carried high levels of an immune cell called the gamma delta (γδ) T cell lived longer on anti-PD-L1 immunotherapy, around 15.4 months, compared with 10.8 months for patients with low levels, according to a study published Oct. 12 in Cancer Cell.
SCLC is one of the most aggressive forms of lung cancer, and most patients are diagnosed after it has already spread. Chemotherapy paired with anti-PD-L1 drug, Tecentriq (atezolizumab) or Imfinzi (durvalumab), is standard first-line treatment for extensive-stage disease, but few patients see responses that last. This is likely due because SCLC tumors switch off MHC class I (MHC-I), the surface machinery that normally flags a cancer cell for killer T cells. Without it, the immune cells those drugs are meant to unleash have trouble finding the tumor.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in